| Hematological findings and complications of COVID‐19 E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ... American journal of hematology 95 (7), 834-847, 2020 | 2113 | 2020 |
| Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis G Papanikolaou, ME Samuels, EH Ludwig, MLE MacDonald, ... Nature genetics 36 (1), 77-82, 2004 | 1250 | 2004 |
| Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis A Roetto, G Papanikolaou, M Politou, F Alberti, D Girelli, J Christakis, ... Nature genetics 33 (1), 21-22, 2003 | 1184 | 2003 |
| Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index E Terpos, R Szydlo, JF Apperley, E Hatjiharissi, M Politou, J Meletis, ... Blood 102 (3), 1064-1069, 2003 | 505 | 2003 |
| Natural history of juvenile haemochromatosis M De Gobbi, A Roetto, A Piperno, R Mariani, F Alberti, G Papanikolaou, ... British journal of haematology 117 (4), 973-979, 2002 | 224 | 2002 |
| Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma E Terpos, M Politou, R Szydlo, JM Goldman, JF Apperley, A Rahemtulla British journal of haematology 123 (1), 106-109, 2003 | 201 | 2003 |
| Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation MC Politou, DJ Heath, A Rahemtulla, R Szydlo, A Anagnostopoulos, ... International journal of cancer 119 (7), 1728-1731, 2006 | 186 | 2006 |
| Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis IP Trougakos, E Terpos, H Alexopoulos, M Politou, D Paraskevis, ... Trends in molecular medicine 28 (7), 542-554, 2022 | 175 | 2022 |
| Oral contraceptives and HRT risk of thrombosis A Gialeraki, S Valsami, T Pittaras, G Panayiotakopoulos, M Politou Clinical and Applied Thrombosis/Hemostasis 24 (2), 217-225, 2018 | 145 | 2018 |
| Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients D O'shea, C Giles, E Terpos, J Perz, M Politou, V Sana, K Naresh, ... Bone marrow transplantation 37 (8), 731-737, 2006 | 142 | 2006 |
| Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined … M Politou, E Terpos, A Anagnostopoulos, R Szydlo, M Laffan, M Layton, ... British journal of haematology 126 (5), 686-689, 2004 | 124 | 2004 |
| The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal … E Terpos, D Mihou, R Szydlo, K Tsimirika, C Karkantaris, M Politou, ... Leukemia 19 (11), 1969-1976, 2005 | 114 | 2005 |
| Significance of macrophage inflammatory protein-1 alpha (MIP-1α) in multiple myeloma E Terpos, M Politou, N Viniou, A Rahemtulla Leukemia & lymphoma 46 (12), 1699-1707, 2005 | 104 | 2005 |
| Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis G Anastasiou, A Gialeraki, E Merkouri, M Politou, A Travlou Blood Coagulation & Fibrinolysis 23 (1), 1-10, 2012 | 95 | 2012 |
| Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity G Papanikolaou, M Politou, E Terpos, S Fourlemadis, N Sakellaropoulos, ... Blood Cells, Molecules, and Diseases 26 (2), 163-168, 2000 | 95 | 2000 |
| No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. M Politou, A Karadimitris, E Terpos, I Kotsianidis, JF Apperley, ... Leukemia research 30 (2), 240-241, 2005 | 74 | 2005 |
| Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma E Terpos, M Politou, R Szydlo, E Nadal, S Avery, E Olavarria, E Kanfer, ... Leukemia 18 (8), 1420-1426, 2004 | 67 | 2004 |
| SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors E Terpos, D Stellas, M Rosati, TN Sergentanis, X Hu, M Politou, V Pappa, ... European journal of internal medicine 89, 87-96, 2021 | 65 | 2021 |
| New insights into the pathophysiology and management of bone disease in multiple myeloma E Terpos, M Politou, A Rahemtulla British journal of haematology 123 (5), 758-769, 2003 | 65 | 2003 |
| VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients CN Markatos, E Grouzi, M Politou, A Gialeraki, E Merkouri, I Panagou, ... Future Medicine Ltd 9 (11), 1631-1638, 2008 | 64 | 2008 |
